Background: Boronate affinity chromatography is widely used, and the method has lately been improved and designed for HbA 1c measurements. We report performance evaluation of the affinity chromatography HbA 1c HPLC analyzer. 
INTRODUCTION
Measurements of HbA 1c and the self-monitoring of blood glucose (SMBG) are an integral part of the current diabetes treatment [1, 2] . Moreover, HbA 1c is rec-ommended also for the diagnosis of diabetes and prediabetes [1, 2] and a growing body of evidence supports its use for cardiovascular risk prediction also in people without diabetes [3, 4] . The widespread use of HbA 1c in clinical practice has been made possible thanks to the progress in standardization and improved quality of analytical methods. The pivotal role of the National Glycohemogobin Standardization Program (NGSP) and IFCC HbA 1c standardization should be emphasized here [5, 6] . Numerous HbA 1c assays utilize only few analytical methodologies. Methods used for HbA 1c measurement include separation of glycated and non-glycated hemoglobin fractions using ion-exchange and affinity chromatography, and capillary electrophoresis or direct HbA 1c measurements using immunoassays or enzymatic methods. Affinity chromatography as a method of HbA 1c quantification has been developed in the shadow of ion-exchange chromatography, which is the reference method in the NGSP [5] .
Here we report the results of performance evaluation of a HbA 1c analyzer utilizing boronate affinity chromatography including a comparison with ion-exchange chromatography.
MATERIALS AND METHODS
The HbA 1c analyzer Premier Hb9210 (Trinity Biotech Plc, Bray Co Wicklow, Ireland) was evaluated in the Department of Clinical Biochemistry Jagiellonian University Medical College Krakow, Poland. The evaluation included imprecision assessment and a comparison of results obtained using the studied analyzer and ionexchange chromatography. Within-run imprecision was assessed based on the results of three series of measurements in three different EDTA blood samples with low and high HbA 1c level, and between-run imprecision was evaluated based on the results of measurements in two HbA 1c control materials provided by the manufacturer (Trinity Biotech Plc). Comparison of methods and analyzers was based on HbA 1c measurements in EDTA whole blood samples collected from patients hospitalized in the University Hospital Krakow, Poland, for treatment monitoring purposes. Blood HbA 1c measurements were routinely performed on the D-10 Hemoglobin Testing System (Bio-Rad Laboratories, Hercules, CA, USA) and a surplus of material was used for measurements done the same day on the evaluated Premier Hb9210 analyzer. The study was approved by the local Ethics Committee and was not associated with any additional burdens for patients. Both methods and analyzers had the NGSP certificates at the time of study. Altogether 349 blood samples were assayed using both methods and analyzers, and 349 pairs of results were compared. Additionally, a set of 50 blood samples from patients with end-stage renal disease (ESRD) hospitalized in the Department of Nephrology, University Hospital Krakow was included in the study. HbA 1c was measured in a surplus of EDTA blood samples collected to perform complete blood count (CBC) for routine diagnostic purposes. These results were analyzed separately. The Premier Hb9210 is an automated boronate affinity HPLC analyzer designed for HbA 1c measurements. Separation of hemoglobin fractions is based on the specific complexing of 1,2-cis-diol groups on the glucose residues of glycated hemoglobin with m-aminophenylboronic acid bound to the column support material. After injection of the diluted blood hemolysate glycated hemoglobin binds to the column support material, while the non-glycated fraction passes through. After complete elution of the non-glycated hemoglobin a reagent displacing the glycated hemoglobin from the binding sites is used to elute this fraction. The absorbance at 413 ± 2 nm of both fractions is measured. After elution and measurement two discrete peaks are obtained in the chromatogram: the non-glycated (HbA 0 ) and glycated hemoglobin (HbA 1 ). Calibration using IFCC traceable calibrators allows for results reporting as HbA 1c calculated as a fraction of total hemoglobin. The reportable HbA 1c range of the Premier Hb9210 is 4% -18% (20 -173 mmol/mol). The D-10 Hemoglobin Testing System is an automated ion-exchange HPLC analyzer. The diluted hemolyzed blood samples are injected into the analytical cartridge to which a programmed buffer gradient of increasing ionic strength is delivered. The hemoglobin fractions are separated based on their ionic interactions depending on the molecules' charge with the cation-exchange resin. The separated hemoglobins pass through the flow cell, where changes in the absorbance at 415 nm are measured. A sample report and a chromatogram containing the separated HbA 1c peak are generated for each sample. The peak area is calculated using an exponentially modified Gaussian (EMG) algorithm that excludes the labile HbA 1c and carbamylated peak areas from the HbA 1c peak area. The reportable HbA 1c range of the D-10 Hemoglobin Testing System is 3.8% -18.5% (18 -179 mmol/mol). The obtained results were not normally distributed and are shown as medians and interquartile differences. Regression and correlation analysis was performed after logarithmic data transformation. For results comparison the Passing-Bablok agreement test and the Bland-Altman difference plot were used. All analyses were performed using the Statistica, version 10 (StatSoft Polska, Krakow, Poland) and MedCalc, version 11.5.0 (MedCalc Software, Ostend, Belgium) software. Table 1 shows within-and between-run imprecision of the evaluated method. The obtained imprecision CVs were in the range from 0.72% to 2.01%. A comparison of the results is presented in Table 2 . HbA 1c levels measured using the Premier Hb9210 ana- (Table 2) . A comparison of HbA 1c levels measured in blood samples collected from the ESRD patients is presented in Table 3 . Median HbA 1c level measured using the Premier Hb9210 analyzer was significantly lower and the mean difference amounted to 0.52 percentage point. Nonetheless, the results correlated well and the PassingBablok test indicated good agreement (Table 3) . 
RESULTS

DISCUSSION
HbA 1c is a product of non-enzymatic attachment of the glucose molecule to the N-terminal valine of one or both globin beta chains. This largest fraction of glycated hemoglobin (HbA 1 ) is commonly used in clinical practice for retrospective blood glucose assessment. Ion-exchange chromatography is designed to directly measure HbA 1c separated from the mixture of glycated hemoglobins in blood sample. In turn, boronate affinity chromatography measures the total glycohemoglobin (HbA 1 ) content in blood. For many years this was a problem solved among others by calculating "the HbA 1c equivalent" derived from measured HbA 1 values. On the other hand, this method is considered less affected by hemoglobin variants and chemically modified (carbamylated, acetylated) hemoglobins. Indeed, boronate chromatography is reported to be less susceptible to interferences from hemoglobin variants, although may be affected by high levels of fetal hemoglobin (HbF) [7] [8] [9] . Ion-exchange chromatography utilizing separation dependent on the molecules' charge has for years been considered more susceptible for interferences from chemically modified hemoglobins. Currently, calibration procedures and data computing allow for the reporting of results obtained using boronate affinity HPLC as HbA 1c values. Moreover, analytical characteristics of both chromatographic HbA 1c methods have been improved lately, which was reflected also in our results. The evaluated Premier Hb9210 analyzer had good within-and between-run precision with the imprecision CVs ranging from 0.72% to 2.01% (Table 1) , thus in accord with the recommended CV < 5% [1] . Our data demonstrate good concordance of the results obtained using the Premier Hb 9210 analyzer and the D-10 Hemoglobin Testing System with the mean difference between the results amounting to 0.13 percentage point (Table 2 ). This is not surprising since both systems are NGSP certified where one of the ion-exchange chromatographic techniques serves as a comparative method [1, 5] [10, 11] . Both affinity chromatography HbA 1c analyzers were characterized by good precision and agreement with comparative methods and considered by the authors suitable for clinical use. The use of HbA 1c in diabetic patients with chronic kidney disease (CKD), particularly advanced (ESRD) is still under discussion due to analytical and diagnostic limitations of this test in a retrospective glycemia assessment [12] . The main analytical issue is carbamylation of hemoglobin -covalent attachment of isocyanic acid to arginine or lysine residues [12] . In CKD this process is enhanced by increased blood urea levels. This chemical modification of hemoglobin has previously been an important issue for the HbA 1c methods based on the molecules' charge including ion-exchange chromatography. Currently used IE-HPLC methods are generally considered less susceptible or free from this interference [9, 13] . Nevertheless, in our study significantly lower median HbA 1c values measured using the Premier Hb 9210 analyzer in ESRD patients with the mean difference amounting to 0.52 percentage point, higher compared to the remaining samples, was found, although with good results correlation and agreement indicated by the Passing-Bablok test (Table 3 ). These findings may be attributed to the interference of carbamylated hemoglobin in the ESRD patients' blood samples affecting the ion-exchange chromatographic method used in the study. This may suggest an advantage of boronate affinity chromatography in HbA 1c measurements in ESRD patients similar to those reported by Little et al. [9] , however, keeping in mind all method-independent limitations of this test in CKD, including altered erythrocyte life span and disturbances in iron status [12, 14, 15] .
CONCLUSION
The Premier Hb9210 analyzer utilizing boronate affinity chromatography for HbA 1c measurements performed well. The system is characterized by low within-and between-run imprecision. Although the Premier Hb 9210 gave lower HbA 1c levels, good results agreement with ion-exchange chromatography on the D-10 Hemoglobin Testing System was found across the wide range of HbA 1c levels usually found in patients with diabetes. Similar analytical performance was found for HbA 1c measurements in ESRD patients. The evaluated Premier Hb9210 analyzer is suitable for routine HbA 1c testing in clinical practice.
